Advertisement

Bisphosphonate-Induced Osteonecrosis of the Jaws (BIONJ)

  • Madhumati Singh
  • Giriraj Sandeep GonegandlaEmail author
Review Article
  • 2 Downloads

Abstract

Introduction

The risk of osteonecrosis of the jaw is greater for patients receiving intravenous bisphosphonates for cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease.

Materials and Methods

This article provides a review of the treatment of Bisphosphonate induced osteonecrosis of jaws.

Conclusion

Bisphonates associated jaw necrosis and its relation to dentisitry and maxillofacial surgery has become common now a days. Proper diagnosis and treatment may help the patients health getting worsen.

Keywords

Bisphosphonate-related osteonecrosis BIONJ Bisphosphonates in maxillofacial surgery Bisphosphonate-induced osteonecrosis 

Notes

References

  1. 1.
    Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral and Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12Google Scholar
  2. 2.
    Marx RE, Stern DS (2002) Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Quintessence, ChicagoGoogle Scholar
  3. 3.
    Marx RE (2009) Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of jaws. J Oral Maxillofac Surg 67:107–119CrossRefGoogle Scholar
  4. 4.
    Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Biphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefGoogle Scholar
  5. 5.
    Rosenberg TJ, Ruggiero SL (2003) Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 61(Suppl 1):60 (Abstract) CrossRefGoogle Scholar
  6. 6.
    Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369–376CrossRefGoogle Scholar
  7. 7.
    Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA, American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw (2008) Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139(12):1674–1677CrossRefGoogle Scholar
  8. 8.
    Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S (2009) Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis 15(8):527–537CrossRefGoogle Scholar
  9. 9.
    Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg 72(10):1938–1956CrossRefGoogle Scholar
  10. 10.
    Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80100CrossRefGoogle Scholar
  11. 11.
    RussellRG CroucherPI, Rogers MJ (1999) Bisphosphonates:pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66–S80CrossRefGoogle Scholar
  12. 12.
    Lin JH, Russell G, Gertz B (1999) Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 101:18–26Google Scholar
  13. 13.
    Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):313Google Scholar
  14. 14.
    Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930–1935CrossRefGoogle Scholar
  15. 15.
    Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324–2333CrossRefGoogle Scholar
  16. 16.
    Bradford W, O’Ryan F (2015) Management of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin N Am 27:517–525CrossRefGoogle Scholar
  17. 17.
    Hellstein JW (2012) Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Spec Care Dent 32(1):33.  https://doi.org/10.1111/j.1754-4505.2011.00229.x CrossRefGoogle Scholar
  18. 18.
    (2006) Oral and Intravenous Bisphosphonate-induced osteonecrosis of the jaws. Quintessence, Chicago, pp 64–72Google Scholar
  19. 19.
    Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63(11):1567–1575CrossRefGoogle Scholar
  20. 20.
    Marx RE (2008) Bisphosphonate-induced osteonecrosis of the jaws: a challenge, a responsibility, and an opportunity. Int J Periodontics Restor Dent 28(1):5–6Google Scholar
  21. 21.
    Sook-Bin W, Hellstein WJ, Kalmar RJ (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761CrossRefGoogle Scholar
  22. 22.
    Marx RE, Cillo JE, Ulloa JJ (2007) Oral bisphosphonate induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefGoogle Scholar
  23. 23.
    Scoletta M, Arata V, Arduino PG, Lerda E, Chiecchio A, Gallesio G, Scully C, Mozzati M (2013) Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg 71(6):994–999CrossRefGoogle Scholar

Copyright information

© The Association of Oral and Maxillofacial Surgeons of India 2019

Authors and Affiliations

  1. 1.RajaRajeswari Dental College and HospitalBengaluruIndia

Personalised recommendations